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Abstract Succinic semialdehyde dehydrogenase deficiency
(SSADHD), a disorder of g-aminobutyric acid (GABA)
metabolism, manifests typically as a nonprogressive neuro-
developmental disorder with cognitive deficiency, neuro-
psychiatric morbidity and epilepsy. Therapy targets
symptomatic seizures and neurobehavioral disturbances. We
report an adolescent female with SSADHD whose unrespon-
siveness to a broad spectrum of antiepileptics was circum-
ventedwithmagnesiumvalproate (MgVPA). Epilepsy remains
well controlled in our patient, with concomitant improvements
in behavioral symptoms and an absence of adverse symptoms.
MgVPA intervention may have utility in SSADHD.
Introduction
The clinical, metabolic, and molecular phenotypes
of SSADHD have been reviewed (Pearl et al. 2003a, b).
The metabolic lesion leads to accumulation of two
neuromodulators, gamma-hydroxybutyric acid (GHB) and
GABA (Wong et al. 2004). The phenotype of SSADHD is
primarily neuropsychiatric, with onset in childhood with
hypotonia and developmental delay. Expressive language
impairment and sleep anomalies are also encountered.
Atypical absence, myoclonic and generalized tonic-clonic
seizures may be observed, as well as photosensitivity,
electrical status epilepticus of sleep and partial seizures
(Pearl et al. 2011). Chronic high endogenous levels of
GABA likely elicit down-regulation of GABA receptors, a
hypothesis supported by data derived from the corresponding
murine model (Cortez et al. 2004; Buzzi et al. 2006; Wu
et al. 2006) and clinical PET and transcranial magnetic
stimulation studies (Pearl et al. 2009, 2011).
Neuropsychiatric morbidity represents an ongoing chal-
lenge in adolescents and adults with SSADHD (Knerr et al.
2008). Behavioral abnormalities include hyperactivity, aggres-
sion, inattention, obsessive-compulsive symptoms and sleep
disturbances, and present treatment challenges especially
when compounded with seizures. Vigabatrin (VGB), an
irreversible inhibitor of GABA transaminase, is predicted to
decrease GHB production (Ergezinger et al. 2003; Gropman
2003; Gibson et al. 1995). Clinical outcomes with VGB,
however, have been inconsistent, and progressive retinopathy
with consequent peripheral vision loss represents an undesir-
able long-term adverse effect (Chiron and Dulac 2011).
Moreover, additional augmentation of GABA levels during
VGB intervention may also be undesirable. Other antiepilep-
tics, including carbamazepine, lamotrigine and ethosuximide
have been variably effective, and benzodiazepines may be
efficacious for moderating agitation and aggression, but
adversely exacerbate ataxia and hypotonia. Additional phar-
maceuticals (e.g., methylphenidate, risperidone, fluoxetine
and fluvoxamine) have been employed in selected cases to
treat behavioral symptoms (Pearl et al. 2003a, b).
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Valproic acid has not been broadly employed in
SSADHD, primarily due to its ability to inhibit any residual
SSADH activity (Simler et al. 1981; Shinka et al 2003).
Anecdotal reports, however, have reported improved
seizure control, without improvements in neurobehavioral
symptoms. We present an adolescent with SSADHD in
whom MgVPA showed both efficacy in seizure control and
an improved behavioral phenotype.
Case Report
The second of two sibs, our patient was born following a
full-term pregnancy with a normal birth and perinatal
course. She presented in infancy with developmental delay
and diffuse hypotonia. Associated manifestations included
hyporeflexia, delayed speech, ataxia, hyperkinesia, short
attention span, stereotyped movements, and EEG abnor-
malities at 3 years of age.
Diagnostic studies at 1 year of age (basic metabolic
panel, cranial magnetic resonance imaging) were normal.
Until 7 years of age no pharmacological interventions were
employed. MgVPA therapy (20 mg/kg/day) was introduced
at 7 years based upon behavioral difficulties and EEG
alterations, without observable adverse effects. At age 13,
MgVPA was stopped because a reasonable level of
performance had been achieved and the parents requested
treatment termination.
One year following cessation of MgVPA administration,
the patient displayed a febrile episode with gradual decay of
her state of vigilance and new onset of complex partial
seizures. The latter were characterized by altered interper-
sonal interactions, fluctuating vigilance, disorientation,
bewildered appearance, expression of fear, dysarthria and
clonus involving primarily the left arm.
At this time (age 14 years), EEG recordings revealed
disorganization of the basic background rhythm with slow
waves of high voltage predominantly in the right hemi-
sphere associated with a pseudo-periodic sharp-wave
discharges mainly localized on the right hemisphere. In
addition, the EEG showed intermixed sharp-wave dis-
charges maximally emanating from the right posterior
temporal regions and rhythmic sequences of theta/delta
activity localized on the same regions (Fig. 1).
Magnetic resonance imaging at this time showed signal
alterations characterized by T2/ FLAIR hyperintense signal,
marked T1 hypointensity, and restricted diffusion of the
bilateral parasagittal frontal lobes and right insula and
temporal lobe (Fig. 2).
There were no changes following gadolinium adminis-
tration, and there was a normal appearance of the circle of
Willis with magnetic resonance angiography.
Additional laboratory evaluations were normal for
ammonia, lactate, hematological panels, and hormonal
assays, as were virological studies other than the evidence
of prior EBV infection. Cerebrospinal fluid showed
Fig. 1 EEG (age 14) showing right periodic lateralized epileptiform discharges (PLEDS) evolving into rhythmic sharp and slow wave ictal
activity maximally from the right posterior temporal region
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normal parameters and no detection of oligoclonal
bands, CMV, EBV, HHV6, HSV1,2, VZV, or Mycoplasma
DNA.
Urine organic acid analysis revealed moderate elevation
of GHB with subtle elevations of 4,5 dihydroxyhexanoic
acid lactone and threo 4,5 hydroxy hexanoic acid. Confir-
mation of SSADHD was established via molecular analysis
that identified a homozygous deletion of two nucleotides in
exon 1 (c.160-161delCT) (as previously described by
Akaboshi et al. 2003). This allele was confirmed as
heterozygous in both parents.
The patient was treated with acyclovir, ceftriaxone,
dexamethasone and barbiturates intravenously, in addition
to a number of enteral antiepileptics (carbamazepine,
oxcarbazepine, levetiracetam, phenobarbital). Intervention
with antiepileptics was subsequently stopped due to
adverse effects. Olanzapine was prescribed for ensuing
psychiatric symptoms, without evidence of clinical
benefit.
At age 15 years, MgVPA (15 mg/kg/day) was reintro-
duced due to ongoing seizure activity and deteriorating
behavior resulting in a gradual improvement in behavior
performances and seizure control. Blood parameters (liver
functions, ammonia, erythrocyte, white cell, and platelet
counts) were cautiously monitored with normal results. One
year following MgVPA reintroduction, our patient
remained seizure-free with marked behavioral improve-
ments. Significantly, there was an improvement in dis-
inhibited behavior including nonrecognition of danger,
aggression and coprolalia. The EEG demonstrated
improved background organization (Fig. 3).
MRI, repeated at 16 years of age, revealed evolution of
the previously documented acute changes (Fig. 4).
Discussion
Our patient with confirmed SSADH deficiency presented
with neurological deterioration characterized by complex
partial seizures and possible limbic encephalitis at 14 years of
age. Although there are concerns about a relative contraindi-
cation to using valproate in this patient population, our
patient had no adverse effects during its use (MgVPA 20 mg/
kg/day) in childhood when selected to treat a combination of
neuropsychiatric deficits and then appeared to benefit from
this agent after presenting with the encephalitic illness.
Magnesium and MgVPA have been successfully
employed in other epileptic and learning disorders (Dósa
et al. 2010; Zou et al. 2010; Porras-Kattz et al. 2011). For
example, Mg has been used to mitigate refractory status
epilepticus in patients with POLG-1 mutations (Pandey
et al. 2010; Visser et al. 2011). With the recent clinical
emphasis on avoiding valproate in children with POLG-1
mutations because of potential precipitation of epilepsia
partialis continuans (Saneto et al. 2010), it is possible that
magnesium had an important therapeutic role in our patient
despite the general clinical tendency to avoid valproate in
SSADH deficiency due to potential inhibition of residual
enzymatic activity (Shinka et al. 2003). Overall, it appears
that valproate was beneficial toward seizure amelioration
and improved behavioral features for our patient’s condi-
tion, and there may have been a therapeutic role for
magnesium, which will require further characterization.
In conclusion, we present therapeutic efficacy of
MgVPA in the behavioral and epileptic phenotype in a
patient with SSADH deficiency. Valproate is not necessar-
ily contraindicated in SSADH deficiency, and magnesium
may have an important role.
Fig. 2 T2/FLAIR MRI showing extensive abnormalities of the bilateral parasagittal frontal lobes and right insula and temporal lobe
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